Checking if a lupus control definition fits Asia-Pacific patients
Part of Immune system & allergy, Skin clinical trials.
This study tests whether a specific lupus “low disease activity” target (called LLDAS) works the same way in people across the Asia-Pacific region. It may help doctors use clearer goals to track how well lupus is controlled.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re diagnosed with systemic lupus erythematosus (SLE), also called lupus
- Your diagnosis must meet specific lupus classification rules (ACR 1997 or SLICC 2012)
- You must be 18 years or older
- You can read, understand, and sign the study consent form in writing
- Your lupus can be newly diagnosed or longstanding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is trying to better understand lupus (SLE) by looking at different types of the disease. It may help doctors find more personalized treatments in the future.
This study looks at the long-term health of people with lupus. It aims to understand how the disease progresses over time.
This trial tests a new treatment called CM355 for people with systemic lupus erythematosus (SLE), a chronic autoimmune disease. It aims to see if the drug can help control disease activity in patients whose lupus is not well managed by current therapies.
This research study aims to better understand systemic lupus erythematosus (SLE), an autoimmune disease where the body's immune system attacks its own tissues. Researchers will evaluate patients with lupus, study genetic factors, and perform optional imaging tests to learn how the disease affects blood vessels and the heart.
This study looks at a “treat-to-target” approach for people with systemic lupus erythematosus (SLE) to help control symptoms to a specific goal. It may help guide medication changes when lupus is not fully calm yet.
This study tests a new drug called LBL-047 in healthy people and in people with mild to moderate lupus. It helps check if the drug is safe and how the body processes it. Participating may help find better treatments for lupus.
Hear when a new Systemic Lupus Erythematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.